Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor- Expressing Advanced Solid Tumors

ZYME Stock  USD 13.10  0.04  0.31%   
About 65% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
  
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancersVANCOUVER, British Columbia, Nov. 05, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed

Read at finance.yahoo.com
Yahoo News
  

Zymeworks Common Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Zymeworks Common Fundamental Analysis

We analyze Zymeworks Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Zymeworks Common is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Zymeworks Common Stock Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zymeworks Common stock to make a market-neutral strategy. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with similar companies.

Peers

Zymeworks Common Related Equities

RLAYRelay Therapeutics   12.42   
0%
100.0%
MRSNMersana Therapeutics   8.06   
0%
64.0%
PRQRProQR Therapeutics   2.11   
0%
16.0%
CYTKCytokinetics   0.30   
0%
2.0%
ANNXAnnexon   0.21   
0%
1.0%
TVTXTravere Therapeutics   0.37   
2.0%
0%
DAWNDay One   0.45   
3.0%
0%
INZYInozyme Pharma   0.67   
5.0%
0%
AKROAkero Therapeutics   0.95   
7.0%
0%
BPMCBlueprint Medicines   0.96   
7.0%
0%
PTGXProtagonist Therapeutics   1.44   
11.0%
0%
CABACabaletta Bio   1.61   
12.0%
0%
RVMDRevolution Medicines   1.82   
14.0%
0%
APLSApellis Pharmaceuticals   1.85   
14.0%
0%
STOKStoke Therapeutics   2.11   
16.0%
0%
YMABY MAbs   2.63   
21.0%
0%
ZNTLZentalis Pharmaceuticals   3.05   
24.0%
0%
TERNTerns Pharmaceuticals   3.18   
25.0%
0%
ALECAlector   4.07   
32.0%
0%
SNDXSyndax Pharmaceuticals   4.75   
38.0%
0%
ARWRArrowhead Pharmaceuticals   4.97   
40.0%
0%
EDITEditas Medicine   5.24   
42.0%
0%
BLUEBluebird Bio   7.14   
57.0%
0%

Complementary Tools for Zymeworks Stock analysis

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device